The global health artificial intelligence market is projected to reach 45 billion dollars by 2026, yet the distribution of development power reveals a concerning concentration. Major technology companies currently control approximately 62 percent of this rapidly expanding market, while public and academic initiatives account for just 3 percent of health AI development.
This disparity underscores an urgent need for alternative governance models, according to policy experts analyzing the sector. The dominance of private corporate interests in health AI development raises significant concerns about equitable access, data privacy, and whether AI systems are optimized for patient benefit or shareholder returns. The research suggests that collaborative investment by middle powers could substantially shift this balance, enabling public institutions to capture a larger share of health AI development while ensuring technologies are designed with patient-centered principles. Rebalancing this equation is essential to prevent technology monopolies from controlling critical healthcare infrastructure.
Read the full article on GMJ Newsroom.
Was this article helpful?
